Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ... [Yahoo! Finance]
Esperion Therapeutics, Inc. (ESPR)
Last esperion therapeutics, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.esperion.com
Company Research
Source: Yahoo! Finance
Sequential Quarterly Net Revenue Growth: Collaboration Revenue: $20.5 million, a 50% increase from $13.7 million in Q3 2023. Research and Development Expenses: $10.4 million, down 30% from $14.9 million in Q3 2023. Selling, General and Administrative Expenses: $40 million, up 20% from $33.2 million in Q3 2023. Total Net Loss: $29.5 million, compared to a net loss of $41.3 million in Q3 2023. Basic and Diluted Net Loss Per Share: $0.15, compared to $0.37 in Q3 2023. Cash and Cash Equivalents: $144.7 million as of September 30, 2024. Full-Year 2024 Operating Expense Guidance: $225 million to $245 million, including $20 million in non-cash expenses related to stock compensation. Warning! GuruFocus has detected 8 Warning Signs with ESPR. Release Date: November 07, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Esperion Therapeutics Inc ( NASDAQ:ESPR ) reported a 53% year-over-year growth in US net product rev
Show less
Read more
Impact Snapshot
Event Time:
ESPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESPR alerts
High impacting Esperion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ESPR
News
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.MarketBeat
- Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y [Yahoo! Finance]Yahoo! Finance
- Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Esperion Reports Third Quarter 2024 Financial Results and Provides a Business UpdateGlobeNewswire
ESPR
Earnings
- 11/7/24 - Miss
ESPR
Sec Filings
- 11/12/24 - Form SC
- 11/8/24 - Form SC
- 11/7/24 - Form 10-Q
- ESPR's page on the SEC website